Compare Neurocrine Biosciences Inc (NBIX) vs Stitch Fix Inc (SFIX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Neurocrine Biosciences Inc vs Stitch Fix Inc — how do they compare? Neurocrine Biosciences Inc trades at $155 (market cap $15.77B), while Stitch Fix Inc trades at $2.9 (market cap $396.27M). The key difference: Neurocrine Biosciences Inc is far larger — about 39.8× Stitch Fix Inc's market cap, and Neurocrine Biosciences Inc is trading nearer its 52-week high, Stitch Fix Inc nearer its low. Which is the better fit depends on your goals.
| NBIX | SFIX | |
|---|---|---|
Market Cap | $15.77B | $396.27M |
Sector | Health | Consumer Cyclical |
52-Week High | $185.50 | $5.80 |
52-Week Low | $123.10 | $2.89 |
Enterprise Value | $15.78B | $283.99M |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Neurocrine Biosciences (NBIX) trades at $155.13, down 0.33% with a bearish technical signal. The company maintains strong fundamentals with 97.91% gross margins and 20.91% net income margin, supported by robust Ingrezza sales growth and Crenessity momentum. Recent news highlights institutional buying interest but also safety concerns around Vykat XR, contributing to recent price volatility.
NBIX presents a compelling growth story with strong profitability and analyst support (86% buy rating), though execution risks and drug safety issues warrant caution. The consensus price target of $207.07 suggests 33% upside potential, making it attractive for investors comfortable with biopharma volatility.
Stitch Fix (SFIX) trades at $2.97, down 2.62% on the day, as the stock faces technical bearish pressure despite showing fundamental improvements. The company has demonstrated progress in its turnaround with three consecutive quarterly earnings beats and narrowing losses, though it remains unprofitable with a -1.43% net margin. Recent news highlights ongoing legal challenges and AI-driven growth initiatives, while analyst sentiment remains cautious with 64% hold ratings.
The outlook suggests a company in transition - improving operational metrics and debt-free balance sheet provide stability, but sustained profitability remains the key challenge. Near-term catalysts include Q2 2026 earnings results and continued execution of AI personalization strategy, though competitive pressures and consumer spending volatility present ongoing risks.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Neurocrine Biosciences Inc
Neurocrine Biosciences, Inc. is a biopharmaceutical company focused on discovering, developing, and commercializing innovative treatments for neurological, endocrine, and psychiatric disorders. The company's portfolio targets conditions such as tardive dyskinesia, endometriosis, and Parkinson's disease. NBIX leverages its expertise in neurobiology and small-molecule drug development to address diseases with significant unmet medical needs.
Read more on NBIX →About Stitch Fix Inc
Stitch Fix Inc offers personal style service for men and women. The company engages in delivering one-to-one personalization to clients through the combination of data science and human judgment. It provides a shipment service called A FIX where the stylist's hand selects items from several merchandises with analysis of client and merchandise data to provide a personalized shipment of apparel, shoes, and accessories suited to the client's needs. The company offers products across categories, brands, product types and price points including Women's, Petite, Maternity, Men's and Plus. It also offers various product types, including denim, dresses, blouses, skirts, shoes, jewelry and handbags, and sells merchandise across various range of price points.
Read more on SFIX →
